Cargando…

Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.

Using a one-stage kinetic chromogenic assay, we studied the procoagulant activity (PCA) of prostatic tissue in an experimental model of prostate cancer in the rat. PCA was present in homogenates of rat prostate glands containing either benign or malignant tumours. The procoagulant activated factor X...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamson, A. S., Luckert, P., Pollard, M., Snell, M. E., Amirkhosravi, M., Francis, J. L.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968672/
https://www.ncbi.nlm.nih.gov/pubmed/8297726
_version_ 1782134791656701952
author Adamson, A. S.
Luckert, P.
Pollard, M.
Snell, M. E.
Amirkhosravi, M.
Francis, J. L.
author_facet Adamson, A. S.
Luckert, P.
Pollard, M.
Snell, M. E.
Amirkhosravi, M.
Francis, J. L.
author_sort Adamson, A. S.
collection PubMed
description Using a one-stage kinetic chromogenic assay, we studied the procoagulant activity (PCA) of prostatic tissue in an experimental model of prostate cancer in the rat. PCA was present in homogenates of rat prostate glands containing either benign or malignant tumours. The procoagulant activated factor X directly and was provisionally characterised as a tissue factor-factor VIIa complex. There was no significant differences in PCA between control rats and rats exposed to carcinogens that did not develop tumour. Levels in rats that developed tumours were significantly higher (P < 0.01) than all other groups and there was a positive correlation between tumour weight and PCA (r = 0.85, P < 0.001). Furthermore, prostatic PCA levels were higher in the metastasis (P < 0.02). We conclude that PCA reflects the malignant phenotype in this animals, the PCA of the primary tumour was compared with that of the corresponding secondary deposit and levels were higher in the metastasis (P < 0.02). We conclude that PCA reflects the malignant phenotype in this model of experimental prostate cancer and suggest that this parameter is worth evaluating as a potential tumour marker in the human disease.
format Text
id pubmed-1968672
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19686722009-09-10 Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer. Adamson, A. S. Luckert, P. Pollard, M. Snell, M. E. Amirkhosravi, M. Francis, J. L. Br J Cancer Research Article Using a one-stage kinetic chromogenic assay, we studied the procoagulant activity (PCA) of prostatic tissue in an experimental model of prostate cancer in the rat. PCA was present in homogenates of rat prostate glands containing either benign or malignant tumours. The procoagulant activated factor X directly and was provisionally characterised as a tissue factor-factor VIIa complex. There was no significant differences in PCA between control rats and rats exposed to carcinogens that did not develop tumour. Levels in rats that developed tumours were significantly higher (P < 0.01) than all other groups and there was a positive correlation between tumour weight and PCA (r = 0.85, P < 0.001). Furthermore, prostatic PCA levels were higher in the metastasis (P < 0.02). We conclude that PCA reflects the malignant phenotype in this animals, the PCA of the primary tumour was compared with that of the corresponding secondary deposit and levels were higher in the metastasis (P < 0.02). We conclude that PCA reflects the malignant phenotype in this model of experimental prostate cancer and suggest that this parameter is worth evaluating as a potential tumour marker in the human disease. Nature Publishing Group 1994-02 /pmc/articles/PMC1968672/ /pubmed/8297726 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Adamson, A. S.
Luckert, P.
Pollard, M.
Snell, M. E.
Amirkhosravi, M.
Francis, J. L.
Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.
title Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.
title_full Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.
title_fullStr Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.
title_full_unstemmed Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.
title_short Procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.
title_sort procoagulant activity may be a marker of the malignant phenotype in experimental prostate cancer.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968672/
https://www.ncbi.nlm.nih.gov/pubmed/8297726
work_keys_str_mv AT adamsonas procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer
AT luckertp procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer
AT pollardm procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer
AT snellme procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer
AT amirkhosravim procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer
AT francisjl procoagulantactivitymaybeamarkerofthemalignantphenotypeinexperimentalprostatecancer